Canada bans some Dr. Reddy's products; Report suggests incentives to fight shortages; Gulf Pharma buys Bangladesh drugmaker;

> Health Canada has stopped allowing imports from a Dr. Reddy's Laboratories plant in Srikakulam that was cited by the FDA with a Form 483 last year. Story

> A report from Pew and others suggests ways to cut drug shortages in the U.S., including offering incentives and price flexibility to companies that expand capacity. Release

> Juno Therapeutics ($JUNO) will lease a manufacturing operation in Bothell, WA, that it would use to produce product for its clinical trials. Release

> George Karavetsos, who was executive assistant U.S. attorney for the Southern District of Florida, has taken over as head of the FDA Office of Criminal Investigations. Report

> UAE-based Gulf Pharma has bought Bangladesh drugmaker RAK Pharmaceuticals to expand in South Asia. Report

Suggested Articles

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.